Earnings

The company reported earnings of $809 million, or 85 cents per share, up from $695 million, or 72 cents per share, a year ago. On an adjusted basis, earnings came in at $773 million, or 81 cents per share – above analysts’ view of 75 cents per share.

Revenue
Revenue for the quarter was $19.6 billion, up from $18.3 billion last year, Analysts expected to see revenue $19.48 billion.

Although Walgreen’s valuation is not overly expensive, it is still not a “cheap” stock at 27 × 2015 earnings estimates. The company benefits from low competition, with CVS Health (CVS) as its main competitor. Fund managers considering a stake in WAG will be more likely to add to positions if the stock pulls back.

Investors seeking exposure to WAG may consider a mutual fund investment. The funds below currently hold the highest stakes in the company.

By investing in one of the funds above, investors are able to gain exposure to a diverse group of holdings and industries. Investors interested in WAG may also be interested in CVS Health (CVS)

Shares of WAG are up 30% YTD.